Farxiga Cuts Risk of Kidney Disease in Patients with Type 2 Diabetes

Published on
By : dLife Editors

Astra Zeneca announced promising results of a phase 3 trial of Farxiga, which showed to reduce the progression of kidney disease or renal death in patients with Type 2 diabetes as much as 47%.

The data were presented recently at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, Calif. and simultaneously published in The Lancet Diabetes & Endocrinology.

Additionally, Farxiga reduced the relative risk of a cardio-renal composite of kidney function decline, ESRD, or renal or cardiovascular (CV) death by 24% compared to placebo.

The study evaluated 17,160 patients with Type 2 diabetes and predominantly preserved renal function, irrespective of underlying atherosclerotic CV disease (ASCVD).

People with diabetes have a six-to-twelve times higher risk of developing ESRD and are approximately twice as likely to develop chronic kidney disease (CKD) than those without.

Farxiga is an inhibitor of SGLT2 indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

Farxiga is not approved to reduce the risk of renal or CV death or to slow the progression of kidney disease.

“Heart failure and renal diseases are two of the most common and early complications experienced by people living with Type 2 diabetes, and are too often overlooked,” said Elisabeth Björk, senior vice president, head of late-stage Development,  cardiovascular, renal and metabolism, bioPharmaceuticals R&D.

“They contribute to a growing economic burden on the global healthcare system and can lead to fatal outcomes for patients. These data continue to offer clinically relevant evidence of the early cardio-renal effects of Farxiga,” she added.

While ESRD was a rare event in the trial, the incidence was lower in the Farxiga arm compared to placebo. The renal-specific outcome was consistent across subgroups regardless of eGFR or urinary albumin-to-creatinine ratio (UACR) category, whether they had established ASCVD or multiple CV risk factors.

For full details, and to view more information on Farxiga tablets, see the company press release.


  1. Astra Zeneca. (2019, June 10). FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes. Business Wire. Retrieved June 12, 2019, from https://www.businesswire.com/news/home/20190610005198/en